 Kenneth Malcolm
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium abscessus | 11 | 2025 | 115 | 4.060 |
Why?
| | Mycobacterium Infections, Nontuberculous | 16 | 2025 | 357 | 3.160 |
Why?
| | Neutrophils | 30 | 2025 | 1274 | 2.730 |
Why?
| | Host-Pathogen Interactions | 4 | 2025 | 368 | 1.770 |
Why?
| | Cystic Fibrosis | 16 | 2025 | 1102 | 1.690 |
Why?
| | Phagocytosis | 7 | 2025 | 387 | 1.050 |
Why?
| | Azithromycin | 4 | 2020 | 97 | 0.870 |
Why?
| | Immunity, Humoral | 1 | 2025 | 115 | 0.860 |
Why?
| | Interferons | 2 | 2016 | 195 | 0.770 |
Why?
| | Lipopolysaccharides | 11 | 2025 | 888 | 0.760 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 2590 | 0.700 |
Why?
| | Immunity, Innate | 3 | 2025 | 824 | 0.650 |
Why?
| | Klebsiella pneumoniae | 2 | 2018 | 46 | 0.610 |
Why?
| | Pseudomonas | 1 | 2018 | 30 | 0.590 |
Why?
| | Pseudomonas aeruginosa | 8 | 2022 | 348 | 0.570 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.550 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 224 | 0.540 |
Why?
| | Nontuberculous Mycobacteria | 7 | 2025 | 201 | 0.540 |
Why?
| | Anti-Bacterial Agents | 11 | 2024 | 1818 | 0.520 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2004 | 316 | 0.400 |
Why?
| | Pseudomonas Infections | 5 | 2022 | 221 | 0.400 |
Why?
| | Neutrophil Activation | 1 | 2013 | 85 | 0.390 |
Why?
| | Reactive Oxygen Species | 4 | 2020 | 624 | 0.380 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.380 |
Why?
| | Staphylococcus aureus | 3 | 2015 | 433 | 0.370 |
Why?
| | Mycobacterium | 1 | 2013 | 110 | 0.360 |
Why?
| | Superoxides | 5 | 2018 | 217 | 0.350 |
Why?
| | Bacteria | 1 | 2018 | 867 | 0.350 |
Why?
| | Sputum | 5 | 2025 | 305 | 0.330 |
Why?
| | Microbial Viability | 3 | 2018 | 91 | 0.310 |
Why?
| | Immunoglobulin G | 2 | 2025 | 898 | 0.310 |
Why?
| | Biofilms | 5 | 2014 | 265 | 0.290 |
Why?
| | Extracellular Traps | 2 | 2018 | 53 | 0.270 |
Why?
| | Immunoglobulin M | 2 | 2025 | 287 | 0.250 |
Why?
| | Interleukin-8 | 3 | 2020 | 271 | 0.250 |
Why?
| | Humans | 45 | 2025 | 138651 | 0.250 |
Why?
| | Mannose-Binding Lectin | 1 | 2025 | 21 | 0.230 |
Why?
| | Phage Therapy | 1 | 2025 | 16 | 0.230 |
Why?
| | Extracellular Space | 2 | 2018 | 129 | 0.220 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1746 | 0.220 |
Why?
| | Cell Separation | 3 | 2016 | 317 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2002 | 761 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2025 | 145 | 0.220 |
Why?
| | Complement C3 | 1 | 2025 | 201 | 0.210 |
Why?
| | Tobramycin | 4 | 2016 | 52 | 0.200 |
Why?
| | Toll-Like Receptors | 3 | 2017 | 189 | 0.190 |
Why?
| | Cytokines | 8 | 2018 | 2080 | 0.190 |
Why?
| | GTP-Binding Proteins | 1 | 2003 | 152 | 0.190 |
Why?
| | Antimalarials | 1 | 2022 | 32 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 7 | 2011 | 280 | 0.180 |
Why?
| | Complement Activation | 1 | 2025 | 403 | 0.180 |
Why?
| | Primary Cell Culture | 2 | 2020 | 171 | 0.180 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 140 | 0.180 |
Why?
| | Case-Control Studies | 3 | 2020 | 3523 | 0.180 |
Why?
| | Pneumonia, Bacterial | 3 | 2013 | 114 | 0.170 |
Why?
| | Bacteriophages | 1 | 2022 | 98 | 0.170 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 22 | 0.170 |
Why?
| | RNA Splicing | 2 | 2023 | 270 | 0.160 |
Why?
| | Chloroquine | 1 | 2020 | 52 | 0.160 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 315 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4315 | 0.150 |
Why?
| | Sirolimus | 1 | 2020 | 277 | 0.140 |
Why?
| | Intracellular Space | 1 | 2018 | 68 | 0.140 |
Why?
| | Autophagy | 1 | 2020 | 285 | 0.140 |
Why?
| | Lung | 9 | 2024 | 4106 | 0.130 |
Why?
| | Respiratory System | 1 | 2018 | 157 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 428 | 0.130 |
Why?
| | Aztreonam | 1 | 2016 | 11 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2003 | 735 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 633 | 0.130 |
Why?
| | Signal Transduction | 3 | 2020 | 5086 | 0.120 |
Why?
| | Mice | 14 | 2024 | 17814 | 0.120 |
Why?
| | Survival Analysis | 2 | 2016 | 1309 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 415 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 849 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.120 |
Why?
| | Interferon-alpha | 1 | 2016 | 195 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 351 | 0.110 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2851 | 0.110 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2015 | 81 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2022 | 2815 | 0.110 |
Why?
| | Cell Movement | 4 | 2013 | 969 | 0.110 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2014 | 59 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 571 | 0.110 |
Why?
| | Oxidants | 1 | 2014 | 112 | 0.110 |
Why?
| | Deoxyribonucleases | 2 | 2011 | 24 | 0.110 |
Why?
| | Phagocytes | 1 | 2014 | 103 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 896 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2014 | 138 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 73 | 0.100 |
Why?
| | Odds Ratio | 1 | 2016 | 1044 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2011 | 1244 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 375 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 157 | 0.100 |
Why?
| | Rhinitis | 1 | 2015 | 171 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1482 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 35 | 0.100 |
Why?
| | Prospective Studies | 5 | 2025 | 7554 | 0.090 |
Why?
| | Male | 13 | 2025 | 68260 | 0.090 |
Why?
| | Sinusitis | 1 | 2015 | 237 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2015 | 522 | 0.090 |
Why?
| | Animals | 15 | 2024 | 37217 | 0.090 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2011 | 7 | 0.090 |
Why?
| | Macrophages | 4 | 2023 | 1543 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 285 | 0.090 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 259 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 245 | 0.090 |
Why?
| | Actins | 3 | 2009 | 419 | 0.090 |
Why?
| | Neutrophil Infiltration | 3 | 2013 | 108 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 350 | 0.090 |
Why?
| | Chemokine CXCL5 | 1 | 2011 | 12 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2025 | 10923 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 39 | 0.080 |
Why?
| | Lipids | 1 | 2015 | 675 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4092 | 0.080 |
Why?
| | Interleukin-17 | 1 | 2011 | 118 | 0.080 |
Why?
| | Species Specificity | 1 | 2011 | 581 | 0.080 |
Why?
| | Female | 12 | 2025 | 73763 | 0.080 |
Why?
| | Viruses | 1 | 2011 | 161 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 525 | 0.070 |
Why?
| | Retroviridae | 1 | 2008 | 103 | 0.070 |
Why?
| | Burns | 1 | 2013 | 341 | 0.070 |
Why?
| | cdc42 GTP-Binding Protein | 2 | 2006 | 22 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 955 | 0.070 |
Why?
| | Peptides | 2 | 2011 | 976 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 408 | 0.070 |
Why?
| | Transgenes | 1 | 2008 | 185 | 0.070 |
Why?
| | Adult | 8 | 2025 | 38201 | 0.070 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 66 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1109 | 0.070 |
Why?
| | Bone Marrow | 1 | 2008 | 299 | 0.070 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2007 | 46 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 935 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2014 | 499 | 0.060 |
Why?
| | Middle Aged | 4 | 2020 | 33604 | 0.060 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 115 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2006 | 87 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 5697 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 364 | 0.060 |
Why?
| | Up-Regulation | 3 | 2006 | 851 | 0.060 |
Why?
| | Inflammation | 5 | 2022 | 2850 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 44 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 322 | 0.060 |
Why?
| | Toll-Like Receptor 4 | 2 | 2007 | 275 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 322 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1438 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 191 | 0.060 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1032 | 0.050 |
Why?
| | Membrane Microdomains | 1 | 2004 | 35 | 0.050 |
Why?
| | Transcription, Genetic | 4 | 2008 | 1470 | 0.050 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 29 | 0.050 |
Why?
| | Inflammation Mediators | 2 | 2011 | 513 | 0.050 |
Why?
| | Enzyme Precursors | 1 | 2003 | 15 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 71 | 0.050 |
Why?
| | NF-kappa B | 4 | 2013 | 678 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2004 | 87 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 320 | 0.050 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 17 | 0.050 |
Why?
| | Zymosan | 1 | 2023 | 66 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 13305 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 195 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2003 | 13 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 20 | 0.050 |
Why?
| | Bacterial Load | 2 | 2015 | 68 | 0.050 |
Why?
| | eIF-2 Kinase | 1 | 2003 | 31 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 133 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2003 | 71 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 347 | 0.050 |
Why?
| | Enzyme Activation | 4 | 2008 | 810 | 0.050 |
Why?
| | Escherichia coli | 1 | 2007 | 827 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10252 | 0.050 |
Why?
| | Toll-Like Receptor 2 | 1 | 2003 | 117 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2005 | 396 | 0.050 |
Why?
| | Interferon Type I | 1 | 2003 | 141 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 368 | 0.050 |
Why?
| | Gene Expression | 2 | 2008 | 1488 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2003 | 201 | 0.040 |
Why?
| | Ciprofloxacin | 2 | 2013 | 26 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2013 | 376 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 274 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 394 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2022 | 595 | 0.040 |
Why?
| | Trans-Activators | 1 | 2003 | 385 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 431 | 0.040 |
Why?
| | Apoptosis | 2 | 2008 | 2546 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1034 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 3028 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 319 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7677 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2002 | 488 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 6851 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 21 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 649 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2172 | 0.030 |
Why?
| | Chemokine CXCL1 | 2 | 2011 | 76 | 0.030 |
Why?
| | Cell Migration Inhibition | 2 | 2011 | 17 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2011 | 141 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 41 | 0.030 |
Why?
| | Imidazoles | 3 | 2002 | 239 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 155 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2011 | 5798 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 1006 | 0.030 |
Why?
| | Aged | 2 | 2015 | 24024 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1471 | 0.030 |
Why?
| | Cathelicidins | 1 | 2015 | 41 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 404 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 215 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2014 | 41 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2030 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 561 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2002 | 3307 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1765 | 0.030 |
Why?
| | Enzyme Inhibitors | 3 | 2002 | 847 | 0.030 |
Why?
| | Gentamicins | 1 | 2015 | 52 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1805 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 75 | 0.030 |
Why?
| | NADPH Oxidases | 1 | 2014 | 140 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 184 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2011 | 1352 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 180 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1935 | 0.030 |
Why?
| | Asthma | 1 | 2005 | 1888 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2003 | 159 | 0.020 |
Why?
| | Spleen | 1 | 2015 | 523 | 0.020 |
Why?
| | Chemokine CCL2 | 2 | 2003 | 116 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 200 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2013 | 326 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 230 | 0.020 |
Why?
| | Fibrinogen | 1 | 2013 | 173 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 329 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3987 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 368 | 0.020 |
Why?
| | Down-Regulation | 2 | 2006 | 635 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 182 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 573 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 27 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 388 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 42 | 0.020 |
Why?
| | Epithelium, Corneal | 1 | 2011 | 43 | 0.020 |
Why?
| | Corneal Ulcer | 1 | 2011 | 21 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 626 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 984 | 0.020 |
Why?
| | Genome | 1 | 2013 | 299 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 102 | 0.020 |
Why?
| | Methacrylates | 1 | 2011 | 117 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 239 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2749 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 466 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 747 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3984 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2876 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5112 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 85 | 0.020 |
Why?
| | Pyridines | 2 | 2002 | 494 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2013 | 893 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 90 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 335 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4555 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2011 | 299 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 234 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 174 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2007 | 28 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 50 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 132 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 76 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2480 | 0.010 |
Why?
| | Keratinocytes | 1 | 2007 | 251 | 0.010 |
Why?
| | Child | 2 | 2020 | 21921 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 138 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 150 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 10 | 0.010 |
Why?
| | rac GTP-Binding Proteins | 1 | 2004 | 36 | 0.010 |
Why?
| | Vital Capacity | 1 | 2005 | 312 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 26 | 0.010 |
Why?
| | Syk Kinase | 1 | 2003 | 21 | 0.010 |
Why?
| | Anthracenes | 1 | 2003 | 32 | 0.010 |
Why?
| | rho GTP-Binding Proteins | 1 | 2004 | 60 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 488 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2004 | 83 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5520 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1233 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4181 | 0.010 |
Why?
| | Chemokines | 1 | 2004 | 226 | 0.010 |
Why?
| | Dexamethasone | 1 | 2005 | 375 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 508 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 98 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2004 | 325 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1317 | 0.010 |
Why?
| | Cholesterol | 1 | 2004 | 403 | 0.010 |
Why?
| | Protein Phosphatase 2 | 1 | 2002 | 40 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 2002 | 77 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 112 | 0.010 |
Why?
| | Aminopyridines | 1 | 2002 | 102 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 1123 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 665 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 144 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 476 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2002 | 88 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2008 | 1102 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1992 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 21564 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2003 | 462 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 768 | 0.010 |
Why?
| | Homeostasis | 1 | 2004 | 614 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1092 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2174 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2155 | 0.010 |
Why?
| | Proteome | 1 | 2002 | 469 | 0.010 |
Why?
|
|
Malcolm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|